Results for tag: "Clinical Oncology Next Generation Sequencing"

Clinical Oncology Next Generation Sequencing (NGS) is a type of genomics technology used to identify genetic mutations in cancer cells. It is used to diagnose and monitor cancer, as well as to develop personalized treatments. NGS enables the sequencing of large amounts of DNA in a single experiment, allowing for the detection of multiple mutations in a single sample. This technology has revolutionized the field of oncology, providing clinicians with a more comprehensive view of a patient's cancer. NGS is used to identify mutations in cancer cells that can be targeted with specific treatments. It can also be used to monitor the effectiveness of treatments and to detect the emergence of drug resistance. Additionally, NGS can be used to identify biomarkers that can be used to predict a patient's response to treatment. Companies in the Clinical Oncology NGS market include Illumina, Thermo Fisher Scientific, BGI, Agilent Technologies, and QIAGEN. Show Less Read more